Sales Performance - Su Tai Shen's main product, Su Tai Sheng, accounted for 90% of total sales, generating approximately 1.1 billion in revenue in 2015, leading the market with the highest share among four competitors [1] - Sales of Shu Tai Qing reached around 100 million, with a market potential of 700-800 million annually in bowel preparation, positioning it as a first-line treatment [1][2] - Shu Tai Qing's sales growth was between 10%-20%, down from previous years' growth rates of over 30% [2] Research and Development - The company focuses on research in nerve damage, with ongoing projects for second and third-generation Su Tai Sheng, and gene therapy targeting hepatitis B and HIV [2] - Clinical trial applications for these projects are expected to be submitted in the following year [2] - The company is also exploring new products, with Su Tai Sheng showing over 20% growth in the first quarter compared to previous years [3] Future Strategy - The company aims to innovate in drug development and has established subsidiaries in the US and Hong Kong for talent acquisition and investment purposes [2] - Plans to increase sales include raising unit prices and expanding market coverage, especially in response to price reductions in the bidding process [3][4] Financial Insights - In 2015, the profit growth rate was 8%, with a non-recurring profit growth rate of 10%, meeting the criteria for the first phase of the stock incentive plan [4] - The company is considering early-stage investments in projects and technologies in the US [4] Market Opportunities - The market for the new drug, Qushi Chloride Capsules, is expected to grow due to increasing public awareness and demand, particularly as it addresses a new market segment [5] - The safety profile of Qushi Chloride is favorable, as it does not cross the blood-brain barrier, enhancing patient compliance [5]

Group 1: Company Overview - Shuyatshen (Beijing) Biopharmaceutical Co., Ltd. is identified with the stock code 300204 [1] - The investor relations activity took place on November 22, 2016 [2] Group 2: Investor Relations Activities - The activity type was a specific object investigation, with participation from various investment firms including Tianfeng Securities and Dongxing Securities [2] - The main topics discussed included company operations, research and development status, investment overview, and product sales [2]

舒泰神（北京）生物制药股份有限公司接待投资者调研纪要 舒泰神调研纪要 时间：2017 年 5 月 19 日 来访单位: 东兴证券、中信建投证券、华安资产、湾流投资、相聚资 本管理有限公司、北京壹玖资产管理公司、中融国际信 托有限公司、建信基金、中冀投资、远策投资 接待人：马莉娜 一、董事会秘书马莉娜介绍 2017 年公司发展情况： 2017 年中，公司的经营没有特别大的变化。在这里我主要简单 介绍一下产品、研发及公司未来的发展战略。舒泰神主要是在研发、 生产、销售全部流程为一体的公司，这是公司主要定位。在这里我 主要说一下公司销售、研发、和未来一段时间发展情况。 销售方面，新版医保目录的出台和未来一两年的招投标政策， 会让公司的销售面临一些比较严峻的挑战。从新版医保目录（2017 版）出来以后，对于神经生长因子的安全性、有效性和质量可控性 方面是一种肯定，但医疗体制改革的大方向会给神经生长因子带来 一些需要克服的困难。在 4 个上市的鼠神经生长因子产品中，销售 格局可能会有一些的变化。舒泰清一直列在医保目录里面，公司新 上市的产品舒唯欣（曲司氯铵胶囊）现在已经进入了大约 10 家医院 来进行销售。招投标方面， ...

Group 1: Market Position and Competitive Advantage - The company holds a significant market share in the pharmaceutical industry, ranking 29th among 39 companies in the "People's Finance Innovation Drug Index" [2] - Key products, Sutai Sheng and Shuitai Qing, are positioned within the top three in the market [3] - The company has developed a comprehensive competitive advantage through years of operation in the research, production, and commercialization of innovative biopharmaceuticals [3] Group 2: Future Plans and Market Demand - The company is considering the growing market demand due to population aging and has plans to address diseases related to this demographic [3] - The 2021 revenue target is set at no less than 471.5 million yuan, with expectations to register at least three drug production licenses, including two innovative biopharmaceuticals [4] - The company aims to enhance its marketing strategies, including online and offline integration, to maintain sales performance and market share for its products [4] Group 3: Research and Development Focus - The company has established a robust R&D pipeline, focusing on innovative biopharmaceuticals, with multiple projects expected to enter the IND application stage in the coming years [5] - Current R&D efforts are concentrated on treatment for neurodegenerative diseases, infectious diseases, and autoimmune diseases [5] - The company is confident in its ability to continuously provide safe and effective therapeutic drugs through its structured R&D phases [4][5] Group 4: Acquisitions and Strategic Moves - The acquisition of 100% of Sichuan Kaikang, now renamed Sichuan Shuitai Shen Pharmaceutical Co., is aimed at enhancing the company's sales platform and operational capabilities [4] - The company is actively working to maximize the value of this platform to support its overall business development [4] Group 5: Regulatory and Market Challenges - The company anticipates that its key products, Sutai Sheng and Shuitai Qing, will not enter the national centralized procurement directory in the short term [4] - The company is closely monitoring the market for Shuitai Qing to create retail demand and mitigate the impacts of centralized procurement [4]

Group 1: Company Overview - Shuotai Shen (Beijing) Biopharmaceutical Co., Ltd. is listed under the stock code 300204 [1] - The investor relations activity took place on May 19, 2021, from 15:30 to 16:30 [2] Group 2: Investor Relations Activity - The activity was categorized as a specific object survey [2] - Participants included various financial institutions such as Guosheng Securities Research Institute, CITIC Asset Management, and others [2] Group 3: Meeting Details - The meeting was held on the Guosheng Securities conference call platform [2] - Key representatives from the company included Ms. Marina, the Secretary of the Board, and Mr. Wang Chao, the Deputy General Manager [2] Group 4: Main Content - The main content included an introduction to the company's basic situation [2] - There was an interactive Q&A session with investors [2]

舒泰神(北京)生物制药股份有限公司 2022 年第三季度报告 证券代码：300204 证券简称：舒泰神 公告编号：2022-48-01 （一） 主要会计数据和财务指标 舒泰神(北京)生物制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1. 董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 2. 公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3. 第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 135,765,114.00 | -11.66% | 382,918,4 ...

R&D Investment and Development - The company reported a significant increase in R&D investment, focusing on strategic new product development and exploratory research to enhance its pipeline [6]. - The company plans to optimize its R&D structure and prioritize key projects to mitigate risks associated with drug development and market acceptance [6]. - The company is actively exploring acquisitions and collaborations to expand its R&D capabilities and product offerings [6]. - The company continues to face high risks in innovative drug development due to long cycles and significant investment requirements [6]. - The company is committed to enhancing its R&D level and carefully selecting projects to improve overall business performance [6]. - R&D investment reached CNY 165.66 million, accounting for 67.03% of operating revenue, representing a year-on-year increase of 16.95% [40]. - The company is focused on developing innovative biopharmaceuticals, including monoclonal antibodies and gene therapy drugs, targeting unmet clinical needs [33]. - The company has several ongoing projects in clinical development, including monoclonal antibody drugs for COVID-19 and other therapeutic areas [33]. - The company has established an advanced drug development technology platform, including systems for drug design, screening, and clinical evaluation [47]. - The company aims to stabilize and advance competitive R&D projects in areas such as neurological diseases and infectious diseases towards IND application [39]. - The number of R&D personnel reached 268, accounting for 33.63% of the total workforce, with 59.70% holding a master's degree or above [49]. Financial Performance - The company's operating revenue for the reporting period was ¥247.15 million, a decrease of 9.35% compared to ¥272.63 million in the same period last year [26]. - The net loss attributable to shareholders was ¥82.75 million, representing a 38.35% increase in loss from ¥59.81 million year-on-year [26]. - The net cash flow from operating activities was -¥87.15 million, a decline of 23.24% from -¥70.71 million in the previous year [26]. - The total assets at the end of the reporting period were ¥1.66 billion, down 9.03% from ¥1.83 billion at the end of the previous year [26]. - The sales revenue from the product Shutaqing was ¥168 million, accounting for 68.03% of total revenue, a decrease of 9.43% year-on-year [34]. - The sales revenue from the product Suruizheng was ¥73 million, representing 29.47% of total revenue, down 14.14% from the previous year [34]. - The company achieved operating revenue of CNY 247.15 million, with a net profit attributable to shareholders of CNY -82.75 million, reflecting a significant loss [39]. - The company's revenue for the reporting period was ¥247,153,363.23, a decrease of 9.35% compared to ¥272,632,152.83 in the same period last year [55]. - Research and development expenses increased by 16.95% to ¥165,658,472.49 from ¥141,643,313.95 year-on-year [55]. - The company reported a significant increase in net cash flow from investing activities, rising by 64.64% to ¥164,072,812.91 due to reduced purchases of financial products [55]. Market and Product Development - The company is focused on continuous innovation in its product offerings, particularly in the field of neurotrophic factors and gastrointestinal health [52]. - The company is exploring new retail models and preparing for the commercialization of potential new products, which may diversify its revenue structure in the future [40]. - The company is actively expanding its market presence in the bowel preparation and constipation management sectors, with ongoing projects in the review stage [51]. - The company has established partnerships with third-party institutions to enhance its R&D capabilities and product development [49]. - The company is addressing the risk of talent shortages by enhancing its human resource management and implementing employee incentive plans [101]. - The company is committed to strengthening its market expansion efforts and improving brand recognition in the innovative drug sector [102]. Environmental and Social Responsibility - The company reported a total of 0.2208 tons of NOX emissions, which is below the regulatory limit of 30 mg/m³ [118]. - The company has a user participation rate of 43.84% in the annual shareholders' meeting held on May 12, 2022 [108]. - The company has established a wastewater treatment station with a processing capacity of 30 tons per day, which is operating well [120]. - The company has actively participated in social responsibility initiatives, donating approximately 400,000 yuan to charitable organizations [127]. - The company received the "Environmental Integrity Unit" title in 2022, highlighting its commitment to environmental protection [125]. Corporate Governance and Compliance - The financial report is guaranteed to be accurate and complete by the company's management, ensuring accountability [4]. - The company has not reported any significant changes in its accounting firm, maintaining continuity in financial oversight [135]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity [133]. - The company has implemented measures to ensure that related party transactions do not harm shareholder interests [132]. - The company has not reported any significant changes in its controlling shareholder or actual controller during the reporting period [170]. Shareholder Information - No cash dividends or stock bonuses will be distributed to shareholders for the reporting period [7]. - The company’s total share capital was reported at 476,034,500 shares, with 97.71% being unrestricted shares [162]. - The largest shareholder, Yizhao (Beijing) Pharmaceutical Technology Co., Ltd., holds 37.15% of shares, totaling 176,832,363 shares [166]. - The total number of restricted shares at the end of the period is 5,744,193 [164]. - The report indicates that 1.97% of shares are held by Huatai Securities Asset Management, totaling 9,382,600 shares [166].

Financial Performance - The company's revenue for Q1 2022 was ¥123,340,760.08, representing a 6.83% increase compared to ¥115,456,600.40 in the same period last year[4] - The net profit attributable to shareholders was -¥24,409,475.07, a decrease of 22.61% from -¥19,908,114.39 year-on-year[4] - The company's basic earnings per share decreased by 25.00% to -¥0.05 from -¥0.04 in the same period last year[4] - Net loss for Q1 2022 was CNY 24,409,475.07, compared to a net loss of CNY 19,908,114.39 in Q1 2021, indicating a deterioration in financial performance[28] - The comprehensive income attributable to the parent company's owners for Q1 2022 was -73,058,069.38 CNY, compared to -45,349,095.05 CNY in the same period last year, reflecting a decline[29] Cash Flow - The net cash flow from operating activities was -¥36,899,357.21, reflecting a 21.18% decline compared to -¥30,451,157.09 in the previous year[4] - Cash inflow from operating activities totaled 169,602,753.13 CNY, up from 131,836,228.43 CNY year-over-year, indicating a growth of approximately 28.6%[31] - Cash outflow from operating activities was 206,502,110.34 CNY, compared to 162,287,385.52 CNY in the previous year, resulting in a net cash flow from operating activities of -36,899,357.21 CNY, worsening from -30,451,157.09 CNY[31] - The net increase in cash and cash equivalents for the period was 18,306,773.64 CNY, down from 35,851,527.92 CNY year-over-year[32] - The ending balance of cash and cash equivalents was 103,317,418.33 CNY, compared to 176,425,786.25 CNY at the end of the same period last year[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,737,202,545.50, down 4.91% from ¥1,826,985,153.57 at the end of the previous year[5] - Total liabilities decreased to CNY 259,521,481.24 from CNY 276,246,019.93 in the previous year[25] - The company's trading financial assets decreased to ¥301,522,904.80 from ¥381,456,190.48, reflecting a decline of about 21%[23] - The total equity attributable to shareholders decreased to CNY 1,477,681,064.26 from CNY 1,550,739,133.64 in the previous year[26] Research and Development - The company's R&D expenses increased by 35.68% to ¥1,824,098.27 due to new capitalized R&D projects[9] - Research and development expenses for Q1 2022 were CNY 58,460,631.70, slightly up from CNY 58,287,906.19 in the same period last year[26] Other Financial Metrics - The company's cash received from other operating activities increased by 454.92% to ¥8,912,476.53, primarily due to funding from a key project in Beijing[12] - The company reported a significant increase in other current assets by 1942.99%, totaling an increase of ¥15,347,225.35, attributed to fixed-income financial products purchased during the period[8] - The company's accounts receivable decreased by 33.34%, amounting to a reduction of ¥39,717,041.88, mainly due to improved sales collections[8] - The company's accounts receivable notes increased from ¥38,759,245.44 to ¥43,667,923.97, showing an increase of about 12.5%[23] - Other comprehensive loss for Q1 2022 was CNY 48,648,594.31, compared to a loss of CNY 25,440,980.66 in Q1 2021[28] Shareholder Information - The total number of restricted shares at the end of the period was 5,744,193, with 5,213,820 shares released during the period[17] - The company was unable to complete the issuance of shares to specific targets within the approval period, leading to the expiration of the registration approval[19] Clinical Trials - The company completed the first administration of the STSA-1002 injection in a Phase I clinical trial for severe COVID-19 on January 13, 2022[18] - The first administration of the BDB-001 injection for ANCA-associated vasculitis was completed on February 25, 2022[20] - The company received a drug production license change approval on March 18, 2022, allowing for an increase in production scope and address[20] Audit Status - The first quarter report was not audited[33]

Financial Performance - The company achieved a sales revenue of 584 million yuan in 2021, representing a significant increase of 37.41% compared to the previous year[5]. - The company's operating revenue for 2021 was CNY 584,291,440.90, representing a 37.41% increase compared to CNY 425,212,063.31 in 2020[29]. - The net profit attributable to shareholders for 2021 was a loss of CNY 137,400,196.24, a slight increase in loss of 3.29% from a loss of CNY 133,018,778.36 in 2020[29]. - The net cash flow from operating activities was a negative CNY 162,071,000.83, which is a 41.43% decline compared to a negative CNY 114,597,698.41 in 2020[29]. - The total assets at the end of 2021 were CNY 1,826,985,153.57, a decrease of 1.57% from CNY 1,856,205,798.74 at the end of 2020[30]. - The basic earnings per share for 2021 was -CNY 0.29, a decrease of 3.57% from -CNY 0.28 in 2020[30]. - The company reported a total of CNY 3,045,180.72 in non-recurring gains and losses for 2021, down from CNY 11,292,379.97 in 2020[36]. - The gross profit margin for the pharmaceutical manufacturing industry was 80.90%, a decrease of 0.84% from the previous year[75]. - The company reported a total revenue of 12.33 billion in 2021, an increase from 11.69 billion in 2020, representing a growth of approximately 5.5%[181]. - The company reported a total revenue of 1.5 billion RMB for the year 2021, representing a year-on-year growth of 20%[189]. Research and Development - Research and development expenses reached 363 million yuan, a substantial increase of 48.76% year-on-year[5]. - The company plans to maintain a high level of R&D investment in the near future to support the advancement of clinical projects and commercialization efforts[6]. - The company is focusing on the development of innovative drugs, particularly in the fields of infectious diseases, autoimmune diseases, and neurological disorders[45]. - The company has a comprehensive R&D pipeline that includes monoclonal antibodies, gene therapy, and chemical drugs[44]. - The R&D team consists of 316 members, accounting for 36.20% of total employees, with 53.48% holding master's degrees and 14.87% holding doctoral degrees, ensuring a strong foundation for continuous innovation[61]. - The company is actively advancing clinical trials for multiple innovative biological drugs, including BDB-001 and STSA-1002, with ongoing projects in various stages of development[67]. - The company is committed to continuous innovation and providing safe and effective therapeutic drugs to contribute to human health[45]. - The company plans to accelerate its R&D efforts, focusing on advancing pipeline projects currently in Phase I and II/III clinical trials, with an emphasis on innovative drug development[123]. - The company invested 200 million RMB in research and development, which is 13% of total revenue, to support new technology advancements[189]. - The R&D expenditure for new products and technologies was 300 million RMB, accounting for 20% of total revenue[199]. Market and Product Development - The company is focusing on expanding its market presence in the biopharmaceutical sector, which is considered a strategic emerging industry in China[40]. - The company has experienced a continuous increase in healthcare demand due to rising living standards and an aging population[40]. - The company aims to expand its market presence by transitioning from generic drugs to innovative drugs, driven by new procurement policies[41]. - The marketing system has resumed orderly operations, leading to a significant recovery in sales for the main products, Shutaqing and Sutai Sheng, which have moved away from the sales lows of 2020[55]. - The company is exploring new retail models and preparing for the commercialization of potential new products, which may further enrich its revenue structure in the future[55]. - The company is focusing on expanding its market presence in the bowel preparation and constipation treatment sectors, with ongoing product development in these areas[64]. - The company is exploring potential mergers and acquisitions to strengthen its market position and enhance its operational capabilities[181]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share within the next two years[189]. - The company is focusing on the development of a new cancer treatment, with clinical trials expected to commence in Q3 2022[199]. Challenges and Risks - The net profit for the reporting period was negative, primarily due to increased R&D expenses associated with ongoing projects[5]. - The pharmaceutical industry faces challenges from external policies such as centralized procurement and medical reform, which may impact production and sales[6]. - The company acknowledges the inherent risks in drug development, including long development cycles and market acceptance challenges[7]. - The company recognizes the risks associated with innovative drug development, including high investment and long development cycles, which could impact business and financial conditions[125]. - There is a significant risk of talent shortages in the biopharmaceutical industry, which could hinder the company's growth as it requires a large number of skilled technical and management personnel[125]. - The company faces market expansion and competition risks, relying on accurate estimates of disease prevalence and market acceptance for its drug development strategy[128]. - Continuous innovation in drug development is crucial; failure to launch new drugs or improve existing products may lead to a decline in market share and financial performance[128]. Governance and Management - The governance structure includes a board of directors with seven members, three of whom are independent directors, ensuring objective and fair decision-making[139]. - The company has established various specialized committees within the board, with independent directors holding a majority in most committees, enhancing decision-making quality[139]. - The supervisory board consists of three members, ensuring compliance and effective oversight of major transactions and financial conditions[140]. - The company adheres to legal and regulatory requirements in its governance practices, ensuring transparency and accountability in shareholder meetings[136]. - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making or operational activities[138]. - The company emphasizes accurate and timely information disclosure, with the chairman as the primary responsible person for information disclosure[141]. - The company has established a dedicated team for investor relations, facilitating extensive communication and feedback from investors[141]. - The company has implemented a framework for related party transactions, ensuring transparency and compliance with regulations[149]. - The company has made adjustments to its fundraising projects and investment amounts, reflecting a proactive approach to financial management[148]. - The company has consistently approved the use of idle raised funds for purchasing principal-protected bank financial products or broker income certificates, maintaining a limit of RMB 60 million from 2018 to 2020[114][115]. Strategic Initiatives - The company aims to enhance its internal management mechanisms and core competitiveness to create conditions for long-term development in the face of challenges and opportunities in 2022[122]. - The company plans to enhance its market efforts, focusing on specialized promotion of innovative drugs and improving brand recognition and academic promotion levels[128]. - The company aims to innovate and improve its management model and incentive mechanisms to strengthen internal processes and reduce management risks[129]. - The company has established a new expert committee to guide its strategic initiatives and ensure compliance with industry standards[185]. - The company plans to allocate 18,300 million for supplementary working capital, fully utilizing the amount[106]. - The company is focusing on long-term strategic planning to ensure sustainable development while advancing R&D projects[172].

Revenue and Profitability - Revenue for Q3 2021 reached ¥153,679,651.05, an increase of 18.02% year-over-year, and cumulative revenue for the year-to-date was ¥426,311,803.88, up 43.93% compared to the same period last year[3] - Net profit attributable to shareholders was -¥65,999,771.49, a decrease of 183.87% year-over-year, with year-to-date net profit at -¥125,811,196.48, down 28.08%[3] - Basic earnings per share for Q3 2021 was -¥0.14, a decline of 180.00% year-over-year, and year-to-date basic earnings per share was -¥0.27, down 28.57%[4] - The net loss for the quarter was CNY 125,811,196.48, compared to a net loss of CNY 98,228,383.78 in the same quarter last year, reflecting a decline of 28.1%[35] - The total comprehensive loss for the quarter was CNY 180,407,452.82, compared to a loss of CNY 87,256,275.87 in the previous year[36] Research and Development - Research and development expenses increased by ¥98,133,251.60, representing a 69.47% rise year-over-year, due to ongoing R&D projects[10] - Research and development expenses totaled 241.75 million yuan in the first nine months of 2021, reflecting a significant increase of 65.00% compared to the previous year[19] - Research and development expenses surged to CNY 239,384,890.17, representing an increase of 69.5% compared to CNY 141,251,638.57 in the previous year[35] - The company announced that the injection of STSP-0601 entered Phase II clinical trials after successfully completing Phase I trials in August 2021[20] - The Phase I clinical trial results for STSP-0601 indicated good safety and tolerability in hemophilia patients with inhibitors, showing a dose-dependent effect on coagulation function[20] - BDB-001 injection received new drug clinical trial approval for ANCA-associated vasculitis in August 2021[21] - STSA-1005 injection obtained FDA clinical trial permission for severe COVID-19 treatment in September 2021[22] - STSA-1002 injection is the first project to achieve dual submission and approval in both China and the US for severe COVID-19 treatment[22] - The first subject in the STSA-1002 injection Phase I clinical trial was dosed in the US in September 2021[24] - The company plans to accelerate clinical development and commercialization of products in key areas such as infectious diseases and autoimmune diseases[25] - The company is actively promoting clinical research and development of drugs to meet unmet clinical needs[25] Cash Flow and Financial Position - Cash flow from operating activities showed a net outflow of -¥115,519,046.54, a decrease of 44.49% year-to-date[3] - Cash inflows from operating activities totaled CNY 431,388,799.42, compared to CNY 360,351,589.34 in the previous year[39] - The net cash flow from operating activities was -115,519,046.54 CNY, compared to -79,947,970.04 CNY in the previous year, indicating a decline in operational cash generation[40] - The net cash flow from investment activities improved to 130,725,769.58 CNY from -129,044,834.01 CNY year-over-year, reflecting a positive turnaround in investment returns[40] - Total cash and cash equivalents at the end of the period were 120,533,483.86 CNY, down from 191,141,624.02 CNY in the same quarter last year, showing a decrease of approximately 37%[41] - Cash inflow from financing activities was -35,203,488.77 CNY, a significant decrease from 47,665,466.66 CNY in the prior year, indicating challenges in raising funds[40] - The company received 18,312,960.00 CNY from investment absorption, marking a new source of cash inflow[40] - The cash outflow for investment activities totaled 668,249,297.02 CNY, down from 972,132,836.86 CNY, reflecting a reduction in capital expenditures[40] - The company experienced a foreign exchange loss of -44,008.74 CNY, which impacted the overall cash position[41] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥1,674,624,141.61, a decrease of 9.78% from the end of the previous year[4] - As of September 30, 2021, total current assets decreased to CNY 741.12 million from CNY 903.32 million at the end of 2020, a decline of approximately 17.96%[30] - Total assets decreased to CNY 1.67 billion as of September 30, 2021, down from CNY 1.86 billion at the end of 2020, a reduction of about 9.79%[30] - Total current liabilities decreased to CNY 167.51 million from CNY 208.20 million at the end of 2020, a decrease of approximately 19.54%[31] - Non-current liabilities totaled CNY 62.05 million as of September 30, 2021, compared to CNY 60.50 million at the end of 2020, an increase of about 2.56%[31] - The company's total equity attributable to shareholders decreased to CNY 1,445,056,936.91 from CNY 1,587,506,217.45 year-over-year[32] - The total liabilities and equity amounted to CNY 1,674,624,141.61, down from CNY 1,856,205,798.74 in the previous year[32] - Total liabilities increased to 268,699,581.29 CNY from 278,742,164.28 CNY, indicating a slight reduction in overall debt levels[45] - The company’s equity attributable to shareholders was 1,587,506,217.45 CNY, remaining stable compared to the previous year[46]